Botanix Pharmaceuticals Ltd
ASX:BOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Botanix Pharmaceuticals Ltd
Total Equity
Botanix Pharmaceuticals Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Total Equity
AU$54m
|
CAGR 3-Years
48%
|
CAGR 5-Years
17%
|
CAGR 10-Years
56%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Equity
AU$370.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Equity
AU$338.5m
|
CAGR 3-Years
101%
|
CAGR 5-Years
69%
|
CAGR 10-Years
37%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Equity
AU$90.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Total Equity
AU$56.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
|
Nyrada Inc
ASX:NYR
|
Total Equity
AU$9.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
Glance View
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.
See Also
What is Botanix Pharmaceuticals Ltd's Total Equity?
Total Equity
54m
AUD
Based on the financial report for Dec 31, 2025, Botanix Pharmaceuticals Ltd's Total Equity amounts to 54m AUD.
What is Botanix Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
56%
Over the last year, the Total Equity growth was -42%. The average annual Total Equity growth rates for Botanix Pharmaceuticals Ltd have been 48% over the past three years , 17% over the past five years , and 56% over the past ten years .
